The European Commission earlier defended the bloc against criticism of its slow launch and said its plans would cause the EU to go through “bumps in the road”.
The EU Drug Surveillance Dog withdrew its authorization to extend the Moderna coronavirus on Monday, despite proposing a special meeting as criticism arose over the slow release of the block vaccine.
The Amsterdam-based European Medicines Agency (EMA) said it would resume talks on Wednesday on whether to give the green light to what would be the EU’s second vaccine.
Read also: US FDA panel recommends emergency authorization of Moderna COVID-19 vaccine
Under pressure from EU nations to accelerate, the regulator watched the meeting earlier to decide on approval from January 12 to Wednesday and then again until Monday.
Despite the launch of its vaccination campaign with the Pfizer-BioNTech vaccine on December 27, EU progress has been much slower than in the United States, the United Kingdom or Israel.
Also read: COVID-19 Vaccine Pricing to Help Governments Provide Low or No Pocket Costs: Pfizer
“The EMA committee for discussions with human medicines on the Covid-19 (de) Moderna vaccine did not end today. It will continue on Wednesday, “EMA said on Twitter.
“No further communication will be issued by the EMA today.”
The European Commission earlier defended the bloc against criticism of its slow launch and said its plans would cause the EU to go through “bumps in the road”.
“It is obvious that such a complex approach will always bring difficulties,” spokesman Eric Mamer told reporters.
The Pfizer-BioNTech vaccine – developed in Germany – is the only one currently authorized for use in the European Union since its rapid authorization by the EMA on 21 December.
The United States is using it with the Moderna vaccine, while the United Kingdom began using one of the British pharmaceutical giant, AstraZeneca, on Monday.
EU countries are far behind. France, for example, struck just over 500 people first. Germany has begun immunizing 200,000.
Meanwhile, the Netherlands, the last in the EU to start its vaccination program, said it was announcing the start of the strikes – two days until Wednesday.
The European Commission has said it has bought access to “almost two billion doses” of six potential vaccines – four times the population of the entire European Union.
Jabul Moderna in the US proved to be 94.1% effective in preventing Covid-19, compared to a placebo in a clinical study of 30,400 people, with slightly better performance in younger adults compared to the elderly.
The EMA said last week that the coronavirus vaccine developed by AstraZeneca and Oxford University, which was approved Wednesday in the UK, is unlikely to receive a green light in the EU next month.
The fact that the watchdog moved from London to Amsterdam after Brexit fueled comments about how Britain was able to move faster after leaving the EU.